ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a single arm, open-label, multicenter, phase II study of pembrolizumab (pembro), gemcitabine, vinorelbine, and liposomal doxorubicin (GVD) in patients with relapsed or refractory classic Hodgkin lymphoma (cHL) with response-adapted consolidation. This study will investigate using circulating tumor DNA (ctDNA) at pre-determined time points using Foresight CLARITY LDT, an ultra-sensitive liquid biopsy platform that detects Minimal residual disease (MRD) in patients with B-cell lymphomas using the phased variant enrichment and sequencing technology (PhasEDq) to determine response to study interventions.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony histologicznie klasyczny chłoniak Hodgkina
- •Choroba powróciła lub nie reaguje na poprzednie leczenie (maksymalnie jeden rodzaj poprzedniego leczenia)
- •Co najmniej jedno ognisko nowotworu widoczne w badaniu PET/CT o odpowiedniej wielkości
- •Dobry ogólny stan zdrowia (skala ECOG 0-2)
- •Wystarczająca funkcja wątroby, nerek i krwiotwórczości w badaniach laboratoryjnych
- •Osoby z wirusem hepatitis B muszą mieć niedetektowalny poziom wirusa
- •Osoby z HIV na skutecznym leczeniu mogą uczestniczyć w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (6)
University of California Davis
Davis, United States
University of California San Francisco-Fresno
Fresno, United States
University of California Irvine
Irvine, United States
University of California, San Diego
La Jolla, United States
Unversity of California, Los Angeles
Los Angeles, United States
University of California, San Francisco
San Francisco, United States
Trial contact
UCSF Hematopoietic Malignancies Clinical Trial Recruitment
Nickole Criner
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.